The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States
Open accessAbstract
OBJECTIVE: To assess the cost effectiveness of including preadolescent boys in a routine human papillomavirus (HPV) vaccination programme for preadolescent girls. DESIGN: Cost effectiveness analysis from the societal perspective. SETTING: United States. POPULATION: Girls and boys aged 12 years. INTERVENTIONS: HPV vaccination of girls alone and of girls and boys in the context of screening for cervical cancer. Main outcome measure Incremental cost effectiveness ratios, expressed as cost per quality adjusted life year (QALY) gained. RESULTS: With 75% vaccination coverage and an assumption of complete, lifelong vaccine efficacy, routine HPV vaccination of 12 year old girls was consistently less than $50,000 per QALY gained compared with screening alone. Including preadolescent boys in a routine vaccination programme for preadolescent girls resulted in higher costs and benefits and generally had cost effectiveness ratios that exceeded $100,000 per QALY across a range of HPV related outcomes, scenarios for cervical cancer screening, and assumptions of vaccine efficacy and duration. Vaccinating both girls and boys fell below a willingness to pay threshold of $100,000 per QALY only under scenarios of high, lifelong vaccine efficacy against all HPV related diseases (including other non-cervical cancers and genital warts), or scenarios of lower efficacy with lower coverage or lower vaccine costs. CONCLUSIONS: Given currently available information, including boys in an HPV vaccination programme generally exceeds conventional thresholds of good value for money, even under favourable conditions of vaccine protection and health benefits. Uncertainty still exists in many areas that can either strengthen or attenuate our findings. As new information emerges, assumptions and analyses will need to be iteratively revised to continue to inform policies for HPV vaccination.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cost-Effectiveness in Health and Medicine
(1996) · doi:10.1093/oso/9780195108248.001.0001 · Cited by 7,193
Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases
Garland, S. M., Hernandez-Avila, M., Wheeler, C. M., Perez, G., Harper, D. M., Leodolter, S., Tang, G. W. K., Ferris, D. G., Steben, M., Bryan, J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa061760 · Cited by 1,886
Gold, M. R., Franks, P., McCoy, K. I., & Fryback, D. G. (1998) · Medical Care · doi:10.1097/00005650-199806000-00002 · Cited by 357
Multiparameter calibration of a natural history model of cervical cancer
Kim, J. J., Kuntz, K. M., Stout, N. K., Mahmud, S., Villa, L. L., Franco, E. L., & Goldie, S. J. (2007) · American Journal of Epidemiology · doi:10.1093/aje/kwm086 · Cited by 161
Self-citationKim, J. J., Andres-Beck, B., & Goldie, S. J. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6604023 · Cited by 156
Self-citation
Cited by
Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United States
Chaturvedi, A. K., Engels, E. A., Pfeiffer, R. M., Hernandez, B. Y., Xiao, W., Kim, E., Jiang, B., Goodman, M. T., Sibug-Saber, M., Cozen, W., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.4596 · Cited by 3,638
Dayyani, F., Etzel, C. J., Liu, M., Ho, C.-H., Lippman, S. M., & Tsao, A. S. (2010) · Head & Neck Oncology · doi:10.1186/1758-3284-2-15 · Cited by 529
Risk of Anal Cancer in HIV-Infected and HIV-Uninfected Individuals in North America
Silverberg, M. J., Lau, B., Justice, A. C., Engels, E., Gill, M. J., Goedert, J. J., Kirk, G. D., D'Souza, G., Bosch, R. J., Brooks, J. T., et al. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cir1012 · Cited by 520
Donovan, B., Franklin, N., Guy, R., Grulich, A. E., Regan, D. G., Ali, H., Wand, H., & Fairley, C. K. (2011) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(10)70225-5 · Cited by 380
Head and neck cancer--Part 1: Epidemiology, presentation, and prevention
Mehanna, H., Paleri, V., West, C. M. L., & Nutting, C. (2010) · BMJ · doi:10.1136/bmj.c4684 · Cited by 330
Metadata
- Authors
- Kim, J. J., & Goldie, S. J.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2009-10-08
- Volume
- 339
- Issue
- oct08 2
- Pages
- b3884-b3884
- ISSN
- 0007-1447 (ISSN-L)
- 0959-8138
- 1468-5833
- OpenAlex
- W2090504491
- Cited by
- 232
- References
- 5
- FWCI
- 18.92
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.